Compare FTS & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTS | NTRA |
|---|---|---|
| Founded | 1885 | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0B | 27.0B |
| IPO Year | N/A | 2015 |
| Metric | FTS | NTRA |
|---|---|---|
| Price | $51.19 | $244.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 16 |
| Target Price | $72.00 | ★ $227.69 |
| AVG Volume (30 Days) | 756.4K | ★ 1.7M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | ★ 4.08 | N/A |
| EPS | ★ 2.41 | N/A |
| Revenue | ★ $8,643,898,655.00 | $2,116,676,000.00 |
| Revenue This Year | $13.04 | $32.77 |
| Revenue Next Year | $4.82 | $16.51 |
| P/E Ratio | $21.10 | ★ N/A |
| Revenue Growth | 5.21 | ★ 38.17 |
| 52 Week Low | $40.32 | $125.38 |
| 52 Week High | $52.83 | $245.59 |
| Indicator | FTS | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 80.03 |
| Support Level | $51.10 | $233.67 |
| Resistance Level | $52.56 | $240.18 |
| Average True Range (ATR) | 0.63 | 7.39 |
| MACD | -0.14 | 0.68 |
| Stochastic Oscillator | 18.47 | 97.49 |
Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving roughly 3.5 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.